Full Press Release Details
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed
a Press Release on "Dr. Reddy's to release Q2 FY 20 results on November 1, 2019 Earnings call slated for November 1,
2019 @ 6:30 PM IST / 9:00 AM EDT"
This is for your information.
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
CC:- New York Stock Exchange Inc.(Stock
| DR. REDDY'S LABORATORIES LTD. | CONTACT | |
| 8-2-337, Road No. 3, Banjara Hills, | Investor relationS | Media relationS |
| Hyderabad - 500034. Telangana, India. | AMIT AGARWAL amita@drreddys.com (Ph: +91-40-49002135) | MITALI SARKAR mitali.sarkar@drreddys.com (Ph: +91-40-49002121) |
Reddy's to release Q2 FY 20 results on November 1, 2019
call slated for November 1, 2019 @ 6:30 PM IST / 9:00 AM EDT
Hyderabad, India, October
Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the second quarter ended September
30, 2019 on Friday, November 1, 2019 after the Board Meeting.
| Event | Date and Time | Medium | ||
| Release of financial results | November 1 st , after the Board Meeting | Email, Media, Company website, Business wire | ||
| Press meet presentation | Will be available on the Company's website | URL available on Company's website, www.drreddys.com | ||
| Earnings Call | Nov 1 st , 6:30 PM IST / 9:00 AM EDT | Hosted by the Company (Details below) | ||
| Playback of Earnings Call | After the earnings call till November 8 th , 2019 | Details below | ||
| Transcript of the Earnings call | Will be available on the Company's website | URL available on Company's website, www.drreddys.com |
Following the release,
the management of the Company will host an earnings call to discuss the Company's financial performance. (Dial In and
other details given below)
be available after the earnings call, till November 8th, 2019. For play back dial in phone No: 022 7194 5757 / 022
6663 5757, and Playback Code is 31923.
| Universal Access Number: | +91 22 6280 1219 +91 22 7115 8120 |
| Local Access Number: Available all over India | +91 70456 71221 |
| International Toll Free Number: | USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 |
number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before
and during the call.
Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products
and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major
therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy's
operates in markets across the globe. Our Major markets include - USA, India, Russia & CIS countries, and Europe. For
more information, log on to: www.drreddys.com
Disclaimer: This press release
may include statements of future expectations and other forward-looking statements that are based on the management's current
views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events
to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by
reason of context, the words "may", "will", "should", "expects", "plans", "intends",
"anticipates", "believes", "estimates", "predicts", "potential", or "continue"
and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from
those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets,
credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events
(ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes
in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization
, including related integration issues.
no obligation to update any information contained herein.